Xencor Reports Fourth Quarter and Full Year 2014 Financial Results Conference...
, Feb. 19, 2015 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and...
View ArticleXencor Reports Second Quarter 2015 Financial and Operating Results
, Aug. 4, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and...
View ArticleXencor Reports Second Quarter 2015 Financial and Operating Results (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., Aug. 4, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor and Novo Nordisk Enter Discovery Collaboration Using Xencor's XmAb...
(Source: Xencor Inc) MONROVIA, Calif., Dec. 18, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor and Novo Nordisk Enter Discovery Collaboration Using Xencor's XmAb...
MONROVIA, Calif., Dec. 18, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Showcases Bispecific Antibody Programs at Annual Summit on Practical...
(Source: Xencor Inc) Xencor Showcases Bispecific Antibody Programs at Annual Summit on Practical and Emerging Trends in Multiple Myeloma Posted on March 28, 2014 by xencor MONROVIA, Calif., March 28,...
View ArticleXencor Showcases Bispecific Antibody Programs at Annual Summit on Practical...
MONROVIA, Calif., March 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Provides Update on Two Lead XmAb® Product Candidates and Expansion of...
-- Commenced multi-dose part of Phase 1a trial of XmAb®7195 examining IgE reduction and safety profile - -- Study with subcutaneous formulation of XmAb7195 to begin in 2016 - -- XmAb®13676 named as...
View ArticleXencor Provides Update on Two Lead XmAb® Product Candidates and Expansion of...
(Source: Xencor Inc) MONROVIA, Calif., June 26, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Provides Data Updates on XmAb Bispecific Antibody Programs and...
(Source: Xencor Inc) MONROVIA, Calif., Nov. 6, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor Provides Data Updates on XmAb Bispecific Antibody Programs and...
MONROVIA, Calif., Nov. 6, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Provides Update on Two Lead XmAb® Product Candidates and Expansion of...
MONROVIA, Calif., June 26, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleNational Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV...
(Source: Xencor Inc) , /PRNewswire/ -- (: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic...
View ArticleXencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and...
MONROVIA, Calif., March 7, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Receives Milestone Payment from Merck for Initiation of Phase 1...
(Source: Xencor Inc) Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 Clinical Trial of a Biologic Candidate using XmAb® Antibody Engineering Intellectual Property Posted on April...
View ArticleXencor Receives Milestone Payment from Merck for Initiation of Phase 1...
My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about XNCR MONROVIA, Calif., April 10, 2014 /PRNewswire/ -- Xencor, Inc....
View ArticleXencor Reports Fourth Quarter and Full Year 2015 Financial Results (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., March 7, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Reports Fourth Quarter and Full Year 2015 Financial Results
, March 7, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and...
View ArticleXencor Reports Second Quarter 2014 Financial Results Conference call today at...
, July 31, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and...
View ArticleXencor Reports First Quarter 2016 Financial Results (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., May 2, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View Article